Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan van Lunzen

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 8, 2013
Hepatitis E virus infections in HIV-infected patients in Ghana and CameroonTorsten Feldt, Fred Stephen Sarfo, Alexander Zoufaly, et al.
AIDS (London, England)|February 11, 2014
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsCalvin Cohen, David Wohl, Jose R Arribas, et al.
Lancet (London, England)|March 20, 2004
HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replicationChristoph Hess, Marcus Altfeld, Seddon Y Thomas, et al.
Plos One|September 21, 2011
Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohortMatthias Stoll, Christian Kollan, Frank Bergmann, et al.
AIDS (London, England)|November 25, 2011
Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patientsChristoph Wyen, Björn Jensen, Marcus Hentrich, et al.
AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.
BMC Gastroenterology|June 3, 2014
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infectionMalte H Wehmeyer, Friederike Eißing, Sabine Jordan, et al.
Journal of Leukocyte Biology|February 15, 2017
Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progressionEun-Seong Kim, Christin Ackermann, Ilona Tóth, et al.
British Journal of Haematology|May 15, 2004
Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's diseaseChristian Hoffmann, Kai Uwe Chow, Eva Wolf, et al.
The Journal of Infectious Diseases|August 31, 2006
Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infectionHendrik Streeck, Heiko Jessen, Galit Alter, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 8, 2013
Hepatitis E virus infections in HIV-infected patients in Ghana and CameroonTorsten Feldt, Fred Stephen Sarfo, Alexander Zoufaly, et al.
AIDS (London, England)|February 11, 2014
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adultsCalvin Cohen, David Wohl, Jose R Arribas, et al.
Lancet (London, England)|March 20, 2004
HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replicationChristoph Hess, Marcus Altfeld, Seddon Y Thomas, et al.
Plos One|September 21, 2011
Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohortMatthias Stoll, Christian Kollan, Frank Bergmann, et al.
AIDS (London, England)|November 25, 2011
Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patientsChristoph Wyen, Björn Jensen, Marcus Hentrich, et al.
AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.
BMC Gastroenterology|June 3, 2014
Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infectionMalte H Wehmeyer, Friederike Eißing, Sabine Jordan, et al.
Journal of Leukocyte Biology|February 15, 2017
Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progressionEun-Seong Kim, Christin Ackermann, Ilona Tóth, et al.
British Journal of Haematology|May 15, 2004
Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's diseaseChristian Hoffmann, Kai Uwe Chow, Eva Wolf, et al.
The Journal of Infectious Diseases|August 31, 2006
Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infectionHendrik Streeck, Heiko Jessen, Galit Alter, et al.
Pageof 12